DMA Diamedica Therapeutics

DiaMedica Inc. ("DiaMedica") (TSX VENTURE:DMA), a biotechnology company focused
on diabetes, is pleased to announce that at the Annual and Special General
Meeting (the "AGM") of shareholders of DiaMedica dated September 22, 2011 David
Allan, Michael Giuffre, Rick Pauls, Dawson Reimer, Richard Pilnik and Thomas
Wellner were elected as the board of directors of the Corporation. 


In addition to the election of directors, the shareholders passed all
resolutions placed before them as outlined in the management information
circular dated August 25, 2011, including the re-appointment of KPMG LLP,
Chartered Accounts, as auditors for the upcoming year, the adoption of a
shareholder rights plan, the adoption of an amended and restated stock option
plan, and the adoption of a deferred share unit plan. 


About DiaMedica

DiaMedica is a biopharmaceutical company that has developed novel therapeutic
compounds aimed to improve the lives of patients with diabetes and other major,
medically unmet diseases. DiaMedica's lead compound, DM-199, represents a novel
approach to treating Type 1 and Type 2 diabetes by demonstrating significant
results against three major aspects of these diseases: 1) halting the autoimmune
attack on beta cells; 2) proliferating insulin producing beta cells and 3)
improving glucose control. 


DiaMedica is also developing DM-204, a monoclonal antibody that inhibits the
enzyme glycogen synthase kinase. In preclinical studies, DM-204 significantly
improved glucose control and decreased blood pressure. 


The Company is listed on the TSX Venture Exchange under the trading symbol 'DMA'.

FORWARD-LOOKING STATEMENTS

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such statements
are based on management's exercise of business judgment as well as assumptions
made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate",
"expect", "intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as contained in the
Company's filings with Canadian securities regulatory authorities. Should one or
more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Company undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize.

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024